Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampicillin + cefotaxime versus ampicillin + amikacin for early neonatal sepsis
IRCT20100102002954N22Phase 3Completed
- Sponsor
- Shahroud University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ampicillin, cefotaxime and amikacin in neonatal sepsis (2 arms), sponsored by Shahroud University of Medical Sciences. Primary endpoints: Duration to CRP negativity, Need for intubation and mechanical ventilation and 3 more. Started Nov 2020; status: completed.
02
Drugs
ampicillincefotaximeamikacin
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on IRCT20100102002954N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100102002954N22.